We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Walmart, Roche and Chevron
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 3, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , Roche Holding AG (RHHBY - Free Report) and Chevron Corporation (CVX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Walmart, Roche and Chevron
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart, Roche Holding and Chevron. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Walmart shares have outperformed the Zacks Supermarkets industry in the year to date period (+24.2% vs. +23.1%). The Zacks analyst believes that the company has been benefiting from rising demand for grocery and general merchandise items amid coronavirus-led stay-at-home trends. Stay-at-home trends are also boosting e-commerce sales, which soared 97% in second-quarter fiscal 2021.
During the quarter, sales and earnings beat the consensus mark and grew year over year, with U.S. comps rising for the 24th straight time. In the U.S. segment, both store and online sales remained strong, supported by government stimulus. Clearly, Walmart’s efforts to enhance deliveries are yielding results.
However, the company is seeing high COVID-19-related costs, especially related to special bonuses. Also, price investments are hurting gross margin to an extent.
Shares of Roche have gained +7% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s rise of +8.4%. The Zacks analyst believes that strong demand for its breast cancer drugs is a major upside for Roche. Also, the expansion of portfolio beyond oncology into immunology is a major positive.
Roche’s performance in the second quarter was negatively impacted by the COVID-19 outbreak, as patients defer routine visits to physicians. While the performance in the first quarter was reasonably good, weak performance in the second quarter affected the first-half results. Nevertheless, the company maintained its outlook.
Strong growth in Ocrevus, Perjeta, Tecentriq and Hemlibra countered biosimilar competition for Herceptin, MabThera and Avastin. Label expansion of Tecentriq into additional indications is a positive. Moreover, the company has a few diagnostics tests for COVID-19, which should boost demand for that segment.
Chevron shares have lost -28.5% over the past year against the Zacks Integrated Oil industry’s fall of -39.1%. The Zacks analyst believes that the supermajor’s reserve replacement ratio of 44% is indicative of its inability to add proved reserves to its reserve base to the amount of oil and gas produced.
While the company reported a big Q2 loss, it vowed to keep its dividend and reported impressive U.S. production growth thanks to strength in the Permian Basin. Chevron’s proposed Noble Energy takeover deal is anticipated to expand its footprint in the DJ Basin and the Permian Basin along with cash-generating offshore assets in Israel.
However, Chevron is not immune to commodity price crash, forcing it to cut capex and suspend buybacks. The company’s high oil price sensitivity is a concern too.
Other noteworthy reports we are featuring today include Advanced Micro Devices (AMD) and S&P Global (SPGI).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Walmart, Roche and Chevron
For Immediate Release
Chicago, IL – September 3, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , Roche Holding AG (RHHBY - Free Report) and Chevron Corporation (CVX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Walmart, Roche and Chevron
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart, Roche Holding and Chevron. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Walmart shares have outperformed the Zacks Supermarkets industry in the year to date period (+24.2% vs. +23.1%). The Zacks analyst believes that the company has been benefiting from rising demand for grocery and general merchandise items amid coronavirus-led stay-at-home trends. Stay-at-home trends are also boosting e-commerce sales, which soared 97% in second-quarter fiscal 2021.
During the quarter, sales and earnings beat the consensus mark and grew year over year, with U.S. comps rising for the 24th straight time. In the U.S. segment, both store and online sales remained strong, supported by government stimulus. Clearly, Walmart’s efforts to enhance deliveries are yielding results.
However, the company is seeing high COVID-19-related costs, especially related to special bonuses. Also, price investments are hurting gross margin to an extent.
(You can read the full research report on Walmart here >>>)
Shares of Roche have gained +7% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s rise of +8.4%. The Zacks analyst believes that strong demand for its breast cancer drugs is a major upside for Roche. Also, the expansion of portfolio beyond oncology into immunology is a major positive.
Roche’s performance in the second quarter was negatively impacted by the COVID-19 outbreak, as patients defer routine visits to physicians. While the performance in the first quarter was reasonably good, weak performance in the second quarter affected the first-half results. Nevertheless, the company maintained its outlook.
Strong growth in Ocrevus, Perjeta, Tecentriq and Hemlibra countered biosimilar competition for Herceptin, MabThera and Avastin. Label expansion of Tecentriq into additional indications is a positive. Moreover, the company has a few diagnostics tests for COVID-19, which should boost demand for that segment.
(You can read the full research report on Roche here >>>)
Chevron shares have lost -28.5% over the past year against the Zacks Integrated Oil industry’s fall of -39.1%. The Zacks analyst believes that the supermajor’s reserve replacement ratio of 44% is indicative of its inability to add proved reserves to its reserve base to the amount of oil and gas produced.
While the company reported a big Q2 loss, it vowed to keep its dividend and reported impressive U.S. production growth thanks to strength in the Permian Basin. Chevron’s proposed Noble Energy takeover deal is anticipated to expand its footprint in the DJ Basin and the Permian Basin along with cash-generating offshore assets in Israel.
However, Chevron is not immune to commodity price crash, forcing it to cut capex and suspend buybacks. The company’s high oil price sensitivity is a concern too.
(You can read the full research report on Chevron here >>>)
Other noteworthy reports we are featuring today include Advanced Micro Devices (AMD) and S&P Global (SPGI).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.